Chimeric antigen receptor (CAR) T-cell therapyFDA-approvedSecond-line
Idecabtagene vicleucel
How it works
Redirects T cells to recognize and destroy cancer cells expressing BCMA.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 80% of MM patients achieved a complete or very good partial response, with a median progression-free survival of approximately 1 year.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.